Different Types of Chemotherapies to Treat ASPS

[Yosef Landesman]

Researches from the Memorial Sloan-Kettering Cancer Center NY write:
“We were not able to demonstrate any benefit from CHEMOTHERAPY or radiation (read Kayton et al 2006 on the ASPS Library)”.
Here we will discuss different types of chemotherapy for alveolar soft part sarcoma patients.

[D.ap]

There's been recent discussion of using chemo along with immune therapy..
Please lets respect the patients privacy and maybe discuss the pros and cons--

This write up 1981
long ago huh


Pulmonary resection and chemotherapy for metastatic alveolar soft-part sarcoma.

Baum ES, Fickenscher L, Nachman JB, Idriss F.
Abstract
Alveolar soft-part sarcoma (ASPS) is an unusual tumor of soft tissues; it has invariably ended in death from disseminated disease, and the lung has been the most common site of metastasis. We present a patient with ASPS with bilateral pulmonary metastases who achieved a complete response after bilateral thoracotomies with removal of all gross disease and after combination chemotherapy including vincristine, actinomycin D, cyclophosphamide, and doxorubicin. The patient has now been followed for five years since the appearance of the metastases and has been off therapy for the past 34 months. He shows no evidence of disease. We suggest that multimodality therapy is a reasonable approach in patients with ASPS and pulmonary metastases and that such therapy has the potential for improving survival.
PMID: 7226089
https://www.ncbi.nlm.nih.gov/pubmed/7226089

[D.ap]

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens and Gary Middleton

Abstract
Although cancer chemotherapy has historically been considered immune suppressive, it is now accepted that certain chemotherapies can augment tumor immunity. The recent success of immune checkpoint inhibitors has renewed interest in immunotherapies, and in combining them with chemotherapy to achieve additive or synergistic clinical activity. Two major ways that chemotherapy promotes tumor immunity are by inducing immunogenic cell death as part of its intended therapeutic effect, and by disrupting strategies that tumors use to evade immune recognition. This second strategy in particular is dependent on the drug, its dose, and the schedule of chemotherapy administration in relation to antigen exposure or release. In this Cancer Immunology at the Crossroads article we focus on cancer vaccines and immune checkpoint blockade as a forum for reviewing preclinical and clinical data demonstrating the interplay between immunotherapy and chemotherapy.

https://www.ncbi.nlm.nih.gov/pmc/articl ... po=17.6056


Questions ?

[D.ap]

Cont…

https://www.ncbi.nlm.nih.gov/pmc/articl ... po=17.6056

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies


Introduction

Cancer treatment strategies are based on the rational integration of multiple distinct treatment modalities that together achieve the highest rates of disease control. Surgery and radiation therapies are used to debulk tumors and achieve locoregional disease control. In contrast, systemic therapies are used in early cancers to eradicate micrometastatic disease and increase cure rates, or in widespread incurable cancers to achieve the greatest disease control with the fewest side effects. Standard systemic therapies may include chemotherapies, pathway-specific molecular therapies, and/or tumor-specific monoclonal antibodies. Rational combinations of these systemic therapies are typically designed to impinge on distinct elements of tumor biology to achieve additive or synergistic antitumor effects. Immunotherapy—including vaccines and immune checkpoint blockade—is the newest class of systemic cancer therapies. The ultimate goal of immunotherapy is to establish a durable population of highly active, tumor-specific T cells that can lyse tumor cells and eradicate cancers. Strategically combining immunotherapies with other systemic therapies to harness potential synergies is critical for maximizing their clinical activity and realizing the greatest benefits for cancer patients. Preclinical and clinical work has evaluated mechanisms of immunomodulation by standard chemotherapy agents, revealing drug- and dose-dependent effects on various aspects of the immune system (1, 2). The schedule and sequence of chemotherapy and immunotherapy also impacts tumor immunity in combination regimens (2). These critical variables differentially engage the potential additive and synergistic clinical activities of chemotherapy and immunotherapy, and are important to consider when translating chemoimmunotherapy regimens to the clinic. This Cancer Immunology at the Crossroads article summarizes the current understanding of these issues, and highlights future directions for research.